Top

Published in:

01-01-2010 | Original Article

Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide

Authors: Ronald C. Hendrickson, Vito R. Cicinnati, Andreas Albers, Grzegorz Dworacki, Andrea Gambotto, Ornella Pagliano, Thomas Tüting, Jose I. Mayordomo, Carmen Visus, Ettore Appella, Jeffrey Shabanowitz, Donald F. Hunt, Albert B. DeLeo

Published in: Cancer Immunology, Immunotherapy | Issue 1/2010

Abstract

Gross L (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326–333

Old LJ, Boyse EA, Clarke DA, Caldwell E (1962) Antigenic properties of chemically induced tumors. Ann NY Acad Sci 101:80–106CrossRef

DeLeo AB, Shiku H, Takahashi T, John M, Old LJ (1977) Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J Exp Med 146:720–734CrossRefPubMed

Jaffee EM, Pardoll DM (1996) Murine tumor antigens: is it worth the search? Curr Opin Immunol 8:622–627CrossRefPubMed

Parmiani G, De Filippo A, Novellino L, Castelli C (2007) Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178:1975–1979PubMed

Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261–1263CrossRefPubMed

Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337–365CrossRefPubMed

Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207CrossRefPubMed

Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415–2432CrossRefPubMed

10.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ (2008) Next generation of immunotherapy for melanoma. J Clin Oncol 26:3445–3455CrossRefPubMed

11.

Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ (1999) Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J Immunol 162:3534–3540PubMed

12.

Lu H, Knutson KL, Gad E, Disis ML (2006) The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res 66:9754–9761CrossRefPubMed

13.

Noguchi Y, Chen YT, Old LJ (1994) A mouse mutant p53 product recognized by CD4⁺ and CD8⁺ T cells. Proc Natl Acad Sci USA 91:3171–3175CrossRefPubMed

14.

Matsutake T, Srivastava PK (2001) The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci USA 98:3992–3997CrossRefPubMed

15.

Uenaka A, Nakayama E (2003) Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL). Cancer Sci 94:931–936CrossRefPubMed

16.

Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183:1357–1365CrossRefPubMed

17.

DeLeo AB, Whiteside TL (2008) Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines 7:1031–1045CrossRefPubMed

18.

Frassanito MA, Mayordomo JI, DeLeo RM, Storkus WJ, Lotze MT, DeLeo AB (1995) Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8⁺ cytotoxic T lymphocyte. Cancer Res 55:124–128PubMed

19.

Shu S, Chou T, Rosenberg SA (1986) In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol 136:3891–3896PubMed

20.

Dubey P, Hendrickson RC, Meredith SC, Siegel CT, Shabanowitz J, Skipper JC, Engelhard VH, Hunt DF, Schreiber H (1997) The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 185:695–705CrossRefPubMed

21.

Hendrickson RC, Skipper JC, Shabanowitz J, Slingluff CJ Jr, Engelhard VH, Hunt DF (1997) Use of tandem mass spectrometry for MHC ligand analysis. In: Lefkovits I (ed) Immunology methods manual, vol 2, Sec. 9.4. Academic Press, London, pp 603–610

22.

Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1995) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716–719CrossRef

23.

Wang W, Meadow LR, den Haan JM, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik A, Hendrickson RC, Bishop CE, Hunt DF, Goulmy E, Engelhard VH (1995) Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269:1588–1590CrossRefPubMed

24.

Hunt DF, Yates JR, Shabanowitz J, Winston S, Hauer CR (1986) Protein sequencing by tandem mass spectrometry. Proc Natl Acad Sci USA 83:6233–6237CrossRefPubMed

25.

Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post- translational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527–534CrossRefPubMed

26.

Bergmann CC, Yao Q, Ho CK, Buckwold SL (1996) Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J Immunol 157:3242–3249PubMed

27.

Gileadi U, Gallimore A, Van der Bruggen P, Cerundolo V (1999) Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. Eur J Immunol 29:2213–2222CrossRefPubMed

28.

Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang NS (1997) Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 8:1303–1311CrossRefPubMed

29.

Tuting T, Gambotto A, De Leo AB, Lotze MT, Robbins PD, Storkus WJ (1998) Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Therapy 6:73–80CrossRef

30.

Tüting T, Gambotto A, Robbins PD, Storkus WJ, De Leo AB (1999) Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor Ag β-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Therapy 6:629–636CrossRefPubMed

31.

Nishitani MA, Sakai T, Ishii K, Zhang M, Nakano Y, Nitta Y, Miyazaki J, Kanayama HO, Kagawa S, Himeno K (2002) A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Cancer Gene Ther 9:156–163CrossRefPubMed

32.

Falk K, Rotzschke O, Stevanovi S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290–296CrossRefPubMed

33.

Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117:1195–1203CrossRefPubMed

34.

Weide B, Garbe C, Rammensee HG, Pascolo S (2008) Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 115:33–42CrossRefPubMed

35.

Bodles-Brakhop AM, Draghia-Akli R (2008) DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 7:1085–1101CrossRefPubMed

36.

Walther W, Siegel R, Kobelt D, Knösel T, Dietel M, Bembenek A, Aumann J, Schleef M, Baier R, Stein U, Schlag PM (2008) Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res 14:7545–7553CrossRefPubMed

37.

Leitner WW, Baker MC, Berenberg TL, Lu MC, Yannie PJ, Udey MC (2009) Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen. Blood 113:37–45CrossRefPubMed

38.

Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD (2008) Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res 68:9884–9891CrossRefPubMed

39.

Noguchi Y, Chen YT, Old LJ (1994) A mouse mutant p53 product recognized by CD4 + and CD8 + T cells. Proc Natl Acad Sci U S A 91:3171–3175CrossRefPubMed

40.

Fedoseyeva EV, Boisgérault F, Anosova NG, Wollish WS, Arlotta P, Jensen PE, Ono SJ, Benichou G (2000) CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J Immunol 164:5641–5651PubMed

41.

Noguchi Y, Richards EC, Chen YT, Old LJ (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219–2223CrossRefPubMed

42.

Moeller G, Adamski J (2008) Integrated view on 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 301:7–19CrossRefPubMed

43.

Luu-The V, Tremblay P, Labrie F (2006) Characterization of Type 12 17ß-Hydroxysteroid Dehydrogenase, an Isoform of Type 3 17ß-Hydroxysteroid Dehydrogenase Responsible for Estradiol Formation in Women. Mol Endocrinol 20:437–443CrossRefPubMed

44.

Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, Abecassis J, Wasylyk B (2008) Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene 27:6607–6622CrossRefPubMed

45.

Nagasaki S, Suzuki T, Miki Y, Akahira J, Kitada K, Ishida T, Handa H, Ohuchi N, Sasano H (2009) 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis. Cancer Res 69:1392–1399CrossRefPubMed

Title: Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide
Authors: Ronald C. Hendrickson
Vito R. Cicinnati
Andreas Albers
Grzegorz Dworacki
Andrea Gambotto
Ornella Pagliano
Thomas Tüting
Jose I. Mayordomo
Carmen Visus
Ettore Appella
Jeffrey Shabanowitz
Donald F. Hunt
Albert B. DeLeo
Publication date: 01-01-2010
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 1/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0730-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen

Calicum microdomains form within neutrophils at the neutrophil–tumor cell synapse: role in antibody-dependent target cell apoptosis

Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma

Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells

Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors

Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer